Nephron
Original Paper
Low Nitric Oxide Production in Patients with Chronic Renal FailureBlum M. · Yachnin T. · Wollman Y. · Chernihovsky T. · Peer G. · Grosskopf I. · Kaplan E. · Silverberg D. · Cabili S. · Iaina A.Department of Nephrology, Tel Aviv Medical Centre, Tel Aviv, Israel
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: June 22, 1998
Issue release date: July 1998
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0
ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)
For additional information: https://www.karger.com/NEF
Abstract
Background: Rats with chronic renal failure have a low nitric oxide (NO) production and a diminished NO excretion. The supplementation of L-arginine has an inhibitory effect on the progression of renal insufficiency. Methods: The present study was designed to determine whether chronic renal failure patients have a low NO production. Plasma and urine nitrate (NO3) and nitrite (NO2), stable metabolites of NO, were measured in 83 consecutive patients with chronic renal failure. The 83 chronic renal failure patients were divided into three groups: group 1, mild renal failure (creatinine clearance >60 ml/min/1.73 m2); group 2, moderate renal failure (creatinine clearance >30 <60 ml/min/1.73 m2), and group 3, severe renal failure (creatinine clearance <30 ml/min/1.73 m2). Thirty-three healthy volunteers served as controls. Results: The daily urinary NO excretion was significantly lower in patients with moderate and severe renal failure as compared with those with mild renal failure and normal controls. The lowest values were found in the severe renal failure group. When the 24-hour urinary NO excretion or NO per milligram creatinine and the NO clearance were correlated with the renal function in all patients as a group, these parameters were directly correlated with the creatinine clearance and inversely correlated with the serum creatinine level. The plasma NO concentration was not different between the three chronic renal failure groups, but higher than in the controls. Plasma NO in renal failure patients was not correlated with the creatinine clearance or serum creatinine levels. Conclusions: Chronic renal failure is a state of NO deficiency. Treatment strategies to increase NO production (L-arginine supplementation or other NO compounds) may prove to be useful in maintaining the renal function and slow the progression of renal disease.
Related Articles:
References
- Romero JC, Strick DM: Nitric oxide and renal function. Curr Opin Nephrol Hypertens 1993;2:114–121.
- Sigmon DH, Carretero OA, Beierwaeters WH: Angiotensin dependence of endothelium- mediated renal hemodynamics. Hypertension 1992;20:643–650.
- Baylis C, Harton P, Engels K: Endothelial derived relaxin factor controls renal hemodynamics in the normal rat kidney. J Am Soc Nephrol 1990;1:875–881.
- Zatz R, De Nucci G: Effects of acute nitric oxide inhibition on rat glomerular microcirculation. Am J Physiol 1991;261:F360–F363.
- Raij L, Shultz PJ: Endothelium derived relaxing factor, nitric oxide: Effects on and production by mesangial cells and the glomerulus. J Am Soc Nephrol 1993;3:1435–1441.
- Nathan C: Nitric oxide as a secretory product of mammalian cells. FASEB J 1992;6:3051–3064.
- Grag UC, Hassid A: Inhibition of rat mesangial cell mitogenesis by nitric oxide-generating vasodilators. Am J Physiol 1989;257:F60–F66.
- Grag UC, Hassid A: NO-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774–1777.
-
Raij L: Nitric oxide and the kidney. Circulation 1993;87(suppl V):26–29.
- Qlu C, Engels K, Baylis C: Endothelin modulates the pressor actions of acute systemic nitric oxide blockade. J Am Soc Nephrol 1995;6:1476–1481.
-
Kone BC, Baylis C: Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Am J Physiol 1997;41:F561–F578.
- Ashab I, Peer G, Blum M, Wollman Y, Chernihovsky T, Hassner A, Schwartz D, Cabili S, Silverberg D, Iaina A: Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int 1995;47:1515–1521.
- Aiello S, Noris M, Todeschini M, Zapella S, Benigni A, Zoja C, Corna D, Zoja C, Cavallotti D, Remuzzi G: Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int 1997;52:171–181.
- Reyes AA, Purkerson ML, Karl I, Klahr S: Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis 1992;20:168–176.
- Koifman B, Wollman Y, Bogomolny N, Chernihovsky T, Finkelstein A, Peer G, Scherez J, Blum M, Laniado S, Iaina A, Keren G: Improvement of cardiac performance by intravenous infusion of L-arginine in patients with congestive heart failure. J Am Coll Cardiol 1995;26:1251–1256.
-
Qui C, Baylis C: Chronic nitric oxide blockade (NOB)-induced hypertension is associated with reductions in plasma volume (PV) and nitrite+nitrate (NOx) excretion (abstract). J Am Soc Nephrol 1994;5:549.
- Vennmalm A, Benthin G, Edlung A, Jungerstein L, Kieler-Jansen N, Lundin S, Westfelt UN, Petersson AS, Waagstein F: Metabolism and excretion of nitric oxide in humans. Circ Res 1993;73:1121–1127.
- Castillo L, Sanchez M, Vogt J, Chapman TE, DeRojas-Walker TC, Tannenbaum SR, Ajami AM, Young VR: Plasma arginine, citrulline, and ornithine kinetics in adults, with observations on nitric oxide synthesis. Am J Physiol 1995;268:E360–E367.
- Castillo L, Chapman TE, Sanchez M, Yu YM, Burke JF, Ajami AM, Vogt J, Young VR: Plasma arginine and citrulline kinetics in adults given adequate and arginine-free diets. Proc Natl Acad Sci USA 1993;90:7749–7753.
- Suto T, Losonczy G, Qiu C, Hill C, Samsel L, Ruby J, Charon N, Venuto R, Baylis C: Acute changes in urinary excretion of nitrite + nitrate do not necessarily predict renal vascular NO production. Kidney Int 1995;48:1272–1277.
-
Schmidt RJ, Kuenzig G, Domico J, Samsell L, Sorkin M, Baylis C: NO production as indicated by the stable oxidation products NO2 + NO3 (= NOx) in patients with chronic renal disease (CRD) (abstract 2929): J Am Soc Nephrol 1997;(suppl):796.
-
Vallance P, Leone A, Calver A, Collier J, Moncada S: Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992;20(suppl):60–62.
- Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572–575.
- Corita Y, Ando A, Tsubakihara Y, Mikami H, Kikuchi T, Nakata K: Tissue and blood cell concentration of methylguanidine in rats and patients with chronic renal failure. Nephron 1981;27:35–39.
- Nakamura K, Kazuharu I, Nakano K, Nakai M, Nakamura Y, Hasegawa G, Sawada M, Kondo M, Mori H, Kanatasuna T: Diabetic renal failure and serum accumulation of the creatinine oxidative metabolites creatol and methylguanidine. Nephron 1996;73:520–525.
- MacAllister RJ, Whitley GSJ, Vallance P: Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int 1994;45:737–742.
- Nussler AK, Billiar TR, Liu ZZ, Morris SM: Coinduction of nitric oxide synthase and argininosuccinate synthetase in a murine macrophage cell line: Implications for regulation of nitric oxide production. J Biol Chem 1994;269:1257–1261.
- Morrissey J, McCracken R, Ishidoya S, Klahr S: Partial cloning and characterization of an arginine decarboxylase in the kidney. Kidney Int 1995;47:1458–1461.
- Roccatello D, Mosso R, Ferro M, Polloni P, Fillipi PG: Urinary endothelin in glomerulonephritis patients with normal renal function. Clin Nephrol 1994;41:323–330.
- Laheta V, Salom MGI, Miranda-Guardiola F, Moncada S, Romero JC: Effects of NG-nitro L-arginine methyl ester on renal function and blood pressure. Am J Physiol 1991;261:F1033–F1037.
- Simonson MS, Wann S, Mene P, Dubyak GK, Kester M, Nakazato Y, Sedor JR, Dunn MJ: Endothelin stimulates phospholipase C, Na+/H+ exchange c-fos expression, and mitogenesis in rat mesangial cells. J Clin Invest 1989;83:708–712.
-
Ohlstein EH, Arleth A, Bryan H, Elliott JD, Po Sung C: The selective endothelin ETA receptor antagonist BQ123 antagonizes endothelin I mediated mitogenesis. Eur J Pharmacol 1990;225:732–735.
External Resources
Article / Publication Details
Published online: June 22, 1998
Issue release date: July 1998
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0
ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)
For additional information: https://www.karger.com/NEF
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
